LEADER 03911nam 2200853z- 450 001 9910557502003321 005 20220111 035 $a(CKB)5400000000044536 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/76390 035 $a(oapen)doab76390 035 $a(oapen)76390 035 $a(EXLCZ)995400000000044536 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aEmbedded Pharmacists in Primary Care 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 online resource (94 p.) 311 08$a3-0365-0170-3 311 08$a3-0365-0171-1 330 $aAs healthcare delivery moves from a provider-centric approach to a more patient-centric approach, systems and payers need to reimagine how care and team-based care is delivered to patients and reimbursed. Thus, the goal should be to see the right patient, by the right provider, in the right place, for the right price, and where appropriate, with the use of the right pharmaceutical(s) - "5 P's". There continues to be a reduction in physicians that are pursuing primary care roles in the United States, thus exacerbating the ability to meet patient demand. Most patient encounters begin with or end with the prescribing of medication. Thus, a future where pharmacists are embedded in primary care settings allows these pharmacists to collaborate at the point-of-prescribing (i.e., in-clinic) and provides tremendous benefits to providers and patients. The pharmacist workforce is educated at the doctoral level, yet vastly underutilized and can assist in a collaborative approach in primary care. The collection of articles in the Special Issue "Embedded Pharmacists in Primary Care" highlight examples of models that have included pharmacists in the ambulatory setting providing services in chronic disease management, comprehensive medication management, and care of specific conditions such as diabetes. 606 $aMedicine$2bicssc 606 $aMedicine and Nursing$2bicssc 610 $aacademic 610 $aacademic medical center 610 $aambulatory care 610 $aambulatory pharmacy 610 $achronic care management 610 $aclinical pharmacy 610 $acollaborative practice agreement 610 $acomprehensive medication management 610 $acomprehensive medications management 610 $adiabetes 610 $adissemination 610 $adyslipidemia 610 $aelectronic dashboard 610 $aelectronic health record 610 $aevidence-based pharmacy practice 610 $afamily medicine 610 $agraduate medical education 610 $ahealth outcomes 610 $ahypertension 610 $aimplementation science 610 $ainnovative practice 610 $ainterprofessional 610 $ainterprofessional collaboration 610 $amedical education 610 $an/a 610 $apatient care extender 610 $apharmacist 610 $apharmacist in primary care 610 $apharmacist-physician collaboration 610 $apharmacy 610 $apractice growth 610 $apractice management 610 $apractice transformation 610 $aprimary care 610 $aprimary care team pharmacist 610 $aprimary health care 610 $aquality improvement 610 $ateam-based primary care 615 7$aMedicine 615 7$aMedicine and Nursing 700 $aMacKinnon III$b PhD$4edt$01293420 702 $aLamberton$b PharmD$4edt 702 $aMacKinnon III$b PhD$4oth 702 $aLamberton$b PharmD$4oth 906 $aBOOK 912 $a9910557502003321 996 $aEmbedded Pharmacists in Primary Care$93022606 997 $aUNINA LEADER 05067nam 2201201z- 450 001 9910576878903321 005 20220621 035 $a(CKB)5720000000008386 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/84555 035 $a(oapen)doab84555 035 $a(oapen)84555 035 $a(EXLCZ)995720000000008386 100 $a20202206d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAdvance in the Treatment of Pediatric Leukemia 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (300 p.) 311 08$a3-0365-4167-5 311 08$a3-0365-4168-3 330 $aThe book gives an overview on the progress that has been made in the treatment of acute lymphoblastic leukemia (ALL), of acute and chronic myeloid leukemia (AML, CML) and of juvenile myelomonocytic leukemia (JMML). Leukemia is the most common malignant disease in children, and 80% of patients are diagnosed with ALL and 15-20% with AML, whereas CML and JMML are rather rare. Although ALL was considered an incurable disease until the early 1960s, with the availability of cytotoxic drugs and the start of clinical multicenter studies, ALL has become an almost curable disease with a survival rate exceeding 90 % in high-income countries. These impressive results have mainly been achieved by a deeper understanding of the genomic landscape of the disease and the introduction of risk stratifications based on genetic features and response to chemotherapy as determined by the presence or absence of minimal residual disease (MRD). Immunotherapies including bispecific T-cell Engagers (BiTEs), Chimeric Antigen Receptor (CAR) T cells, monoclonal antibodies and improvements in the outcome of allogeneic stem cell transplantation (HSCT) have shown impressive results in chemorefractory or relapsed patients, and it is anticipated that the cure rate can be further increased. For countries with less resources, therapies have to be adapted to increase survival as well. This book also updates on the progress made in the treatment of AML. As in ALL, risk classification based on genetic factors and response to chemotherapy is most important for therapy guidance. The book also provides updates and guidance for the treatment of CML and JMML. 606 $aChemistry$2bicssc 606 $aResearch & information: general$2bicssc 606 $aResearch and information: general$2bicssc 610 $a5-azacitidine 610 $aABCC4 610 $aacute lymphoblastic leukemia 610 $aacute myeloid leukemia 610 $aacute pancreatitis 610 $aADC 610 $aadvances 610 $aALL 610 $aallogeneic stem cell transplantation 610 $aalternative donors 610 $aAML 610 $aantibody 610 $aantibody-drug conjugate 610 $aB-ALL 610 $aBCL11B 610 $aBCP-ALL 610 $abispecific T-cell engager (BiTE) 610 $aCD19 610 $aCFTR 610 $achildhood acute lymphoblastic leukemia 610 $achildren 610 $achronic myeloid leukemia 610 $aCML 610 $aconditioning regimen 610 $aCOVID-19 610 $adiagnosis 610 $aDUX4 610 $aevolution of CAR T cells 610 $aFc-engineering 610 $aFDA-approved CAR products 610 $afuture directions of CAR T cell therapy 610 $agenome 610 $ahematopoietic stem cell transplantation 610 $aIKZF1 610 $aimmunizations 610 $aimmunotherapy 610 $ajuvenile myelomonocytic leukemia 610 $aL-asparaginase 610 $aleukemia 610 $alimitations and complications of CAR T cell therapy 610 $alow-risk ALL 610 $alymphoblastic leukemia 610 $aminimal residual disease 610 $amyelodysplastic/myeloproliferative disorders 610 $an/a 610 $aNOTCH1 610 $aNUTM1 610 $aother extramedullary relapse 610 $aPAX5 610 $apediatric 610 $apediatric leukemia 610 $aPh-like 610 $apolymorphism 610 $aprognosis 610 $aRAS signaling 610 $arisk-stratified treatment 610 $aSNV 610 $aT-ALL 610 $atargeted therapy 610 $aTcR versus CAR 610 $aTRAIL 610 $atranscriptome 610 $atreatment 610 $atreatment related toxicity 610 $atyrosine kinase inhibitor 610 $axenograft 610 $aZNF384 615 7$aChemistry 615 7$aResearch & information: general 615 7$aResearch and information: general 700 $aHandgretinger$b Rupert$4edt$01326310 702 $aHandgretinger$b Rupert$4oth 906 $aBOOK 912 $a9910576878903321 996 $aAdvance in the Treatment of Pediatric Leukemia$93037296 997 $aUNINA